773 related articles for article (PubMed ID: 25366678)
1. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
2. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Mitin T; George A; Zietman AL; Heney NM; Kaufman DS; Uzzo RG; Dreicer R; Wallace HJ; Souhami L; Dobelbower MC; Sandler HM; Shipley WU
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):67-74. PubMed ID: 26700703
[TBL] [Abstract][Full Text] [Related]
5. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.
Efstathiou JA; Bae K; Shipley WU; Kaufman DS; Hagan MP; Heney NM; Sandler HM
J Clin Oncol; 2009 Sep; 27(25):4055-61. PubMed ID: 19636019
[TBL] [Abstract][Full Text] [Related]
6. Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.
Hafeez S; Horwich A; Omar O; Mohammed K; Thompson A; Kumar P; Khoo V; Van As N; Eeles R; Dearnaley D; Huddart R
Br J Cancer; 2015 May; 112(10):1626-35. PubMed ID: 25897675
[TBL] [Abstract][Full Text] [Related]
7. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
8. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
10. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
11. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
12. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer.
Shipley WU; Kaufman DS; Zehr E; Heney NM; Lane SC; Thakral HK; Althausen AF; Zietman AL
Urology; 2002 Jul; 60(1):62-7; discussion 67-8. PubMed ID: 12100923
[TBL] [Abstract][Full Text] [Related]
13. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
[TBL] [Abstract][Full Text] [Related]
15. Re: Long-Term Outcomes in Patients with Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Gofrit ON
Eur Urol; 2015 Jul; 68(1):165-6. PubMed ID: 26088735
[No Abstract] [Full Text] [Related]
16. Re: Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Chang SS
J Urol; 2015 Jun; 193(6):1931-2. PubMed ID: 25986789
[No Abstract] [Full Text] [Related]
17. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
[TBL] [Abstract][Full Text] [Related]
18. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
Zhang M; Tao R; Zhang C; Shen Z
Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
[TBL] [Abstract][Full Text] [Related]
20. [Radiochemotherapeutic options for bladder cancer].
Weiss C; Sauer R; Rödel C
Aktuelle Urol; 2008 Mar; 39(2):123-9. PubMed ID: 18379965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
